Indication :
MYREPT is indicated for the prophylaxis of acute organ rejection and increased graft and patient survival in patients receiving allogeneic cardiac transplants. Should be used concomitantly with Cyclosporine and Corticosteroids.
MYREPT is indicated for induction and maintenance therapy of adult patients with WHO Class III, IV, V lupus nephritis. This indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were ISN/RPS (2003) Class IV. The evidence for efficacy was based on surrogate endpoints.
Compositions :
Each film-coated caplet contain Mycophenolate mofetil 500 mg
Storage Condition :
Store below 30°C, in airtight container.
